top of page

Local Clinical Trials

Hawaii Pacific Neuroscience:  The Neuroscience Research & Clinical Trial unit at Hawaii Pacific Neuroscience is one of the most sought after clinical trial site in the US for neuroscience conditions because of its reputation for excellence in clinical care and operational excellence in research and clinical trials.

 

For more information:  http://hawaiineuroscience.com/services/research-trials

 

Current clinical trial: https://clinicaltrials.gov/

​

TOZ-CL06 Trial: A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose "Wearing-Off".  Click here to learn more.

​

Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension (RESTORE)(recruiting)

  • 18 years or older and able to stand (with or without limited assistance)

  • ï‚·  Clinical diagnosis of symptomatic orthostatic hypotension associated with Primary Autonomic Failure (PD,

    MSA or PAF) or NDAN or DBH Deficiency

  • ï‚·  A documented drop of at least 20 mmHg in SBP, within 3 minutes of standing. This can either be documented in the patient history or assessed during Screening prior to the first Titration Visit 

​

To download the Hawaii Pacific Neuroscience patient brochure, click here.  

To talk to someone about the trails, contact Rachel at (808) 564-6113

 

 

Pacific Health Research and Education Institute: PHREI is a nonprofit health research institution in Hawaii providing the State with the needed technical and administrative infrastructure to successfully obtain and conduct health research and education programs. PHREI research is uniquely enabled by its central Pacific Rim location and access to multi-generational, ethnically diverse island populations.

 

For more information: http://www.phrei.org/

 

Current clinical trial: http://steadypd3.com/ 

(recruitment for this trial has been completed)

 

We are recruiting recently (within 3 years) diagnosed people with PD for a new clinical trial. The medication being studied is a once a day combination of extended release rasagiline and pramipexole. The trial lasts 14 weeks.

Pharma 2B Clinical Trial Flyer.png
bottom of page